

1634 Inage

PATENT Attorney Docket No. UPA-008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Whitehead

SERIAL NO.:

10/045,360

GROUP NO.:

1634

FILING DATE:

January 22, 2002

EXAMINER:

Jeffrey N. Fredman

TITLE:

METHODS FOR DETERMINING STEROID RESPONSIVENESS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 3rd day of November, 2003.

Date

Brenda T. Kowalczuk

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith is/are:

Transmittal Form (1 pg.); Supplemental Information Disclosure Statement (1 pg.); PTO-1449 (1 pg.); Cited Art C30-C33; this Certificate of First Class Mailing and return receipt postcard.

2705229

	OIPE									
NOV 0 5 2003 EN TRANSMITTAL FORM			Application Serial Number			10/045,360				
			Filing Date			January 22, 2002				
			First Named Inventor			Whitehead				
			Group Art Unit			1634				
			Examiner Name			Jeffrey N. Fredman				
			Attorney Docket No.		1	UPA-008				
			BATCH NO	BATCH NO. (after allowance) Patent No.		Not applicable				
			Patent No.			Not applicable				
			Issue Date			Not applicable				
		EN	CLOSURES (c	heck all that apply)						
☐ Fee	Transmittal Form			e to File Missing	Π	Notice of Appeal to Board				
	Check Attached		Parts of Applie	cation (PTO-1553)		of Patent Appeals and Interferences				
	Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)				
Amendment/Response			Request For Continued Examination (RCE)] Status Inquiry				
	☐ Preliminary ☐ After Final ☐ Affidavits/declaration(s) ☐ Letter to Official		Transmittal	ver of Attorney		Return Receipt Postcard				
						Certificate of First Class Mailing				
	Draftsperson		(Revocation of Frior Fowers)		=	under 37 C.F.R. 1.8				
	including Drawings [Total Sheets]		Terminal Disclaimer			Certificate of Facsimile Transmission under 37 C.F.R. 1.8				
	Petition for Extension of Time	I —		laration and Power Tutility or Design		Additional Enclosure(s) (please identify below)				
 Supplemental Information Disclosure Statement Form PTO-1449 Copies of IDS Citations 			Small Entity Statement CD(s) for large table or computer program							
			Amendment A	After Allowance						
	Document(s)		Request for Co	ertificate of						
Sequence Listing submission Paper Copy/CD		Correction Certificate		of Correction (in						
	☐ Computer Readable Copy	duplicate)		or concensor (in						
	Statement verifying identity of above									
CORRESPONDENCE ADDRESS				SIGNATURE BL	OC	K				
Direct a	Direct all correspondence to: Patent Administrator					Respectfully submitted,				
Testa, Hurwitz & Thibeault, High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100			-7000	Date: November 3, 2 Reg. No. 43,153 Tel. No.: (617) 310- Fax No.: (617) 248-		58 Attorney for Applicant				



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Whitehead

SERIAL NO.:

10/045,360

GROUP NO.:

1634

FILING DATE:

January 22, 2002

EXAMINER:

Jeffrey N. Fredman

TITLE:

METHODS FOR DETERMINING STEROID RESPONSIVENESS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non U.S. patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

Fourth Supplemental Information Disclosure Statement Serial No. 10/045,360 Page 2 of 2 П (3) after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND the requisite Statement is below, AND the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein. It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. **STATEMENT** As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]: 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R.

Respectfully submitted,

1.56(c) more than three months prior to the filing of the Information

Disclosure Statement.

Date: November 3, 2003

Reg. No. 43,153

Tel. No.: (617) 310-8168 Fax No.: (617) 248-7100

2705203

Diana M. Steel

Attorney for Applicant

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

FORM PTO - 1449					ATTORNEY DOCKET NO.: UPA-008						
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					APPLICANT: Whitehead SERIAL NO.: 10/045,360						
					GROUP: Not yet assigned						
U.S. PATENT DOCUMENTS											
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME						FILING DATE IF APPROPRIATE	
						<u></u>					
			FOREI	GN PATE	NT DOCU	MENTS				:	
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY		ENGLISH LANG (Y/N)	
OTHER ART, JOURNAL ARTICLES, ETC.											
EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT.											
	C30 Baumann et al., "Interaction of Cytokine- and Glucocorticoid-Response Elements of Acute-Phase Plasma Protein Genes", The Journal of Biological Chemistry, Vol. 265, No. 36, pp. 22275-22281, December 25, 1990.										
	C31 Nickerson et al., "Automated DNA Diagnostics Using an ELISA-Based Oligonucleotide Ligation Assay", Proc. Natl. Acad. Sci., Vol. 87, pp. 8923-8927, November 1990.										
	C32 Scheidereit et al., "The glucocorticoid Receptor Binds to Defined Nucleotide Sequences Near the Promote of Mouse Mammary Tumour Virus", Nature, Vol. 304, pp. 749-752, August 25, 1983.										
	C33 Tobe et al., "Single-Well Genotyping of Diallelic Sequence Variations by a Two-Color ELISA-Based Oligonucleotide Ligation Assay", Nucleic Acids Research, Vol. 24, No. 19, 1996.									A-Based	
EXAMINER			DATE CONSIDERED								

2705173